Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.45 |
| ▸ | MDM4 | O15151 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12635325 | 0.93 | CASP3 (0.41) | CASP3MDM4TP53TNFTLR2 | |
| SCHEMBL12667232 | 0.86 | CASP3 (0.48) | CASP3MDM4TP53TNFKMT2A | |
| SCHEMBL12635230 | 0.86 | CASP3 (0.50) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL12668872 | 0.80 | CASP3 (0.40) | CASP3MDM4TP53TNFTLR2 | |
| SCHEMBL12635323 | 0.79 | CASP3 (0.45) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL12635334 | 0.79 | CASP3 (0.45) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL12635331 | 0.77 | CASP3 (0.60) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL12635234 | 0.77 | CASP3 (0.60) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL31000709 | 0.76 | CASP3 (0.51) | CASP3MDM4TP53KMT2A | |
| SCHEMBL21404824 | 0.76 | MDM2 (0.54) | CASP3MDM4TP53TNFTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105389-A1 | Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same | OCERA THERAPEUTICS, INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105389-A1 | Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same | GHSR, GHRHR, GIPR | CASP3 2886/4885MDM4 4865/4885TP53 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.